← Volver a todas las respuestas
Why Are My Tremors Still There Even Though My Copper Is Controlled?
Residual tremors after copper normalises are common and do not mean treatment has failed — additional medications such as propranolol or gabapentin may help, but need specialist guidance.
Bringing your copper levels under control is the most important step in treating Wilson disease, but it does not always make tremors disappear right away — and sometimes they do not fully go away at all. This is one of the more frustrating realities of neurological Wilson disease, and it is far more common than many people expect. The good news is that there are targeted medications that can reduce tremor even when the underlying copper burden is already well managed.
Why tremors can persist after copper is controlled
Copper that has accumulated in the brain over months or years leaves behind structural changes in brain tissue — particularly in areas like the basal ganglia and thalamus — that do not simply reverse the moment copper levels drop.1 Think of it like the difference between turning off a fire and assessing the damage the fire left behind. The fuel is gone, but the rooms still need repair.
Neurological recovery in Wilson disease is real and well documented, but it follows its own timetable — often months to a few years after stable copper control is achieved.2 Some patients see dramatic improvement; others are left with a residual tremor that has stabilised rather than progressed. If your neurologist has confirmed that your exchangeable copper and ceruloplasmin are in acceptable range and have been there for some time, the tremor you are still experiencing most likely reflects this kind of incomplete structural recovery, not ongoing active copper toxicity.
That distinction matters enormously for deciding what to do next.
Is this tremor the same as essential tremor, and does that change treatment?
Not exactly — but the practical question of which medications might help overlaps considerably. Wilson-related tremors can look like essential tremor (a postural, action-type shake), a Parkinsonian resting tremor, or a “wing-beating” intention tremor, and sometimes a mix of all three.3 The type of tremor you have influences which medication a neurologist is likely to reach for.
For action and postural tremors (the kind that shows up when you hold your arms out or try to drink from a glass), the evidence base from essential tremor research suggests:
- Propranolol (a beta-blocker) is the most studied first-line agent for this tremor type, with well-established reductions in tremor amplitude.4
- Gabapentin has been shown in a randomised trial to produce comparable benefit to propranolol in essential tremor and is an alternative when propranolol is not well tolerated or is contraindicated (e.g., asthma, low blood pressure, bradycardia).4
For intention and “wing-beating” tremors — the slower, large-amplitude shake that gets worse as you reach for something — neither propranolol nor gabapentin works as reliably. These tremors originate in the cerebellum and thalamic pathways rather than the peripheral loop propranolol modulates. Options in this case are more limited; clonazepam and primidone are sometimes used, and in severe refractory cases movement disorder specialists occasionally consider thalamic deep brain stimulation, though this is rare.5
What the Wilson disease guidelines say
The 2022 AASLD Practice Guidance for Wilson disease explicitly acknowledges that symptomatic treatment of residual neurological symptoms is appropriate once copper is under control, and that these adjunct medications should be managed in collaboration with a neurologist experienced in movement disorders.1 The guidance does not specify doses — those decisions depend on your heart rate, blood pressure, kidney function, and other medications you may be taking.
The EASL guidelines make a similar point: neurological improvement may continue for years after biochemical stabilisation, so patience and longitudinal reassessment are part of the plan alongside any symptomatic therapy.6
Practical questions to bring to your specialist team
When you see your neurologist, it helps to come prepared:
- What type of tremor do I have? Ask whether it is postural, resting, or intention-dominant — this determines which drug class is most likely to help.
- Has my tremor plateaued or is it still slowly improving? If you are only six to twelve months into stable copper control, the evidence suggests continued spontaneous improvement is still possible.
- Are there contraindications to propranolol for me? Asthma, certain cardiac arrhythmias, and very low resting heart rate all affect whether a beta-blocker is safe.
- What is the goal — meaningful functional improvement or complete suppression? Being realistic about targets helps both you and your doctor choose and evaluate treatments.
What about occupational therapy and physical strategies?
Medication is not the only tool. Weighted utensils, wrist weights, and adapted writing tools can meaningfully reduce the functional impact of a tremor without adding a new drug. Occupational therapy is often under-utilised in Wilson disease care and is worth requesting specifically if tremor is affecting your daily tasks — eating, writing, using a phone.5 Some patients find that fatigue, stress, and caffeine worsen their tremor substantially; managing those factors in parallel with medication gives the best result.
The takeaway
Persistent tremor despite controlled copper is common, not a sign of treatment failure, and is worth treating on its own terms. Propranolol and gabapentin are the most evidence-supported options for action-type tremors; the right choice depends on your specific tremor pattern and overall health. A movement disorder neurologist — ideally one who has seen Wilson disease before — is the right person to guide this part of your care, in close communication with your hepatologist or Wilson specialist. You can read more about the range of neurological symptoms Wilson disease causes and how they evolve at /post/early-symptoms and /post/medications-overview.
This article is for general patient education only and does not replace advice from your own medical team. Tremor management requires individual assessment — please discuss any medication changes with your neurologist and Wilson disease specialist before acting on anything you read here.
References
-
Schilsky, Michael L., Eve A. Roberts, Joanna M. Bronstein, Anil Dhawan, et al. “A Multidisciplinary Approach to the Diagnosis and Management of Wilson Disease: 2022 Practice Guidance from the American Association for the Study of Liver Diseases.” Hepatology 77, no. 3 (2022): 1428–1455. https://doi.org/10.1002/hep.32801. ↩↩
-
Litwin, Tomasz, Petr Dusek, and Anna Członkowska. “Neurological Wilson Disease.” In Wilson Disease, edited by Michael L. Schilsky. Amsterdam: Elsevier, 2019. https://doi.org/10.1016/b978-0-12-811077-5.00013-x. ↩
-
Członkowska, Anna, Tomasz Litwin, Petr Dusek, Peter Ferenci, et al. “Wilson Disease.” Nature Reviews Disease Primers 4, no. 1 (2018): 21. https://doi.org/10.1038/s41572-018-0024-5. ↩
-
Gironell, Alexandre, Jaime Kulisevsky, Magi Barbanoj, Daniel López-Villegas, and Guillem Hernández. “A Randomized Placebo-Controlled Comparative Trial of Gabapentin and Propranolol in Essential Tremor.” Archives of Neurology 56, no. 4 (1999): 475–480. https://doi.org/10.1001/archneur.56.4.475. ↩↩
-
Vives-Rodriguez, Ana Lucia, and Theresa Robakis. “Symptomatic Treatment of Residual Neurological or Psychiatric Disease.” In Wilson Disease, edited by Michael L. Schilsky. Amsterdam: Elsevier, 2019. https://doi.org/10.1016/b978-0-12-811077-5.00020-7. ↩↩
-
European Association for Study of the Liver. “EASL Clinical Practice Guidelines: Wilson’s Disease.” Journal of Hepatology 56, no. 3 (2012): 671–685. https://doi.org/10.1016/j.jhep.2011.11.007. ↩
-
Alkhouri, Naim, Regino Gonzalez-Peralta, and Valentina Medici. “Wilson Disease: A Summary of the Updated AASLD Practice Guidance.” Hepatology Communications 7, no. 5 (2023): e0150. https://doi.org/10.1097/hc9.0000000000000150. ↩
-
Tornabene, Alessia, Paola Bini, Matteo Gastaldi, Elisa Vegezzi, and Cecilia Asteggiano. “Neurological Complications Due to Copper Deficiency in the Context of Wilson Disease Treatment: A Case Report.” Neurological Sciences 44 (2023): 3283–3287. https://doi.org/10.1007/s10072-023-07126-8. ↩
Esto es educación para pacientes, no asesoramiento médico. Consulta siempre a tu propio equipo clínico sobre las decisiones de tu tratamiento.